NFG
ECYT

Next Financial Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Next Financial Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,250
Closed -$6K – 2448
2016
Q4 		$6K Hold
2,250
– – ﹤0.01% 1891
2016
Q3 		$7K Buy
2,250
+1,250
+125% +$3.9K ﹤0.01% 1831
2016
Q2 		$3K Hold
1,000
– – ﹤0.01% 1547
2016
Q1 		$3K Hold
1,000
– – ﹤0.01% 1501
2015
Q4 		$4K Hold
1,000
– – ﹤0.01% 1484
2015
Q3 		$4K Hold
1,000
– – ﹤0.01% 1515
2015
Q2 		$5K Hold
1,000
– – ﹤0.01% 1504
2015
Q1 		$6K Hold
1,000
– – ﹤0.01% 1455
2014
Q4 		$6K Hold
1,000
– – ﹤0.01% 1456
2014
Q3 		$6K Hold
1,000
– – ﹤0.01% 2007
2014
Q2 		$7K Buy
+1,000
New +$11.3K ﹤0.01% 862

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Next Financial Group's ECYT Position: Q1 2017 in Review

Next Financial Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 2,250 shares — an estimated $6K sold.

Next Financial Group first reported a position in ECYT in Q2 2014 and held it in 11 quarters. The position peaked at $7K in Q3 2016. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

  • Next Financial Group reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Next Financial Group sold 2,250 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $6K.
  • Next Financial Group first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 11 quarters.
  • Next Financial Group's Endocyte, Inc. Common Stock position peaked at $7K in Q3 2016.
  • 82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Next Financial Group's 13F filing for Q1 2017, filed 8 May 2017.